Good morning. Let me take this opportunity to welcome all of those who have joined the 2026 Annual Meeting of Stockholders of SIGA Technologies, Inc. I am Diem Nguyen, Chief Executive Officer of SIGA. I would like to introduce Larry Miller, SIGA's General Counsel, who will be serving as the secretary of the meeting. Members of SIGA's Board of Directors are attending today's meeting through this webcast. Also attending through this webcast are members of SIGA's senior management team and representatives of PricewaterhouseCoopers, our registered public accountant. This meeting is being held pursuant to proper notice based on the Notice of Annual Meetings of Stockholders, dated April 28th, 2026, concerning the matters to be considered and acted upon in this meeting, and a copy of the proxy statement, annual report, and proxy card provided to the stockholders as of April 17th, 2026, the record date established for this meeting by the Board of Directors, and the proxy statement supplement filed on May 8th, 2026. Barry Shapiro has been appointed to serve as Inspector of Elections for this meeting and has signed an oath, which will be filed with the minutes of the meeting. The Inspector of Elections has reported that they are present in person or represented by proxy at the meetings of the holders of more than 35,862,048 shares, constituting a majority of 71,724,097 shares of common stock of SIGA Technologies, Inc outstanding and entitled to vote at the meeting as of the record date. There is, therefore, a quorum present, and the meeting is competent to transact business. It is now 10:33 A.M., and I declare the polls now open. Please note if you have already submitted your proxy, there is no need to vote during the meeting unless you would like to change your vote. Voting during the meeting will revoke your prior proxy. The polls will close following the presentation of the items of business. In addition, I would like to remind everyone that stockholders may submit a written question during the next few minutes following the instructions on our virtual meeting portal. Before we begin today's event, please note that any forward-looking statements made on the behalf of SIGA during the meeting are based on management's current expectations and observations and are subject to risks and uncertainties that cause actual results to differ from the forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statements to reflect events or changed circumstances after this meeting. For a discussion of factors that could cause the result to differ, please see SIGA's filings with the Securities and Exchange Commission. I would now like to begin today's event with a few brief remarks. It's a pleasure to be here with you today. We are proud to stand with the partners who share our purpose of supporting governments around the globe in strengthening our long-term preparedness strategies against biological threats, particularly smallpox. The case for action has never been clearer. In an environment marked by heightened geopolitical instability and an increasing risk of outbreak, robust preparedness strategies are essential. Smallpox and other high-consequence threats require proactive, sustained investment, and ready access to effective medical countermeasures. Maintaining appropriate stockpiles is a critical component of that preparedness. We believe TPOXX plays an important role in meeting a potential smallpox threat. 2025 was a year of disciplined operational execution and solid financial performance for SIGA. We generated $95 million in total revenues with $88 million in product sales. This included successfully delivering 79 million of oral and IV TPOXX to the U.S. Strategic National Stockpile, or SNS, as well as 6 million to an international customer. Additionally, we returned $43 million to shareholders through a special cash dividend in each of 2025 and 2026. This reflects the strength of our balance sheet and our commitment to capital management and long-term shareholder value creation. In parallel, we continue to advance two key initiatives that we have potential to further strengthen TPOXX's role in smallpox preparedness. We are advancing our pediatric formulation for children unable to take capsule form, and we're planning to submit a supplemental NDA with the FDA within the next 12 months for post-exposure prophylactic use of oral TPOXX. Both programs are designed to address important unmet preparedness needs and expand access to this critical medical countermeasure. Building on these efforts, we achieved several other important milestones in 2025, including securing $27 million in funding from the U.S. government to support development of pediatric formulation and IV TPOXX manufacturing activities. We believe these actions reflect continued importance of TPOXX to our U.S. government. In the meantime, we continue to engage with the U.S. government over a new procurement contract, which would represent a continuation of a partnership spanning more than a decade. In closing, SIGA entered 2026 with a clear sense of purpose, defined by strategic focus, financial discipline, and durable government partnerships. Our differentiated TPOXX franchise, combined with a proven track record of execution, uniquely positions us to support global health security while continuing to deliver long-term value for our shareholders. To our shareholders, thank you for your continued support and trust. Our mission remains clear: to protect communities from smallpox. While we've made meaningful progress, our work continues. We cannot do this alone, and we're grateful to have you with us on our journey. Thank you. This concludes my prepared remarks. We will address shareholder questions after Larry Miller goes through the order of business for this meeting. I will now turn the meeting over to Larry. Thank you, Diem. Please note that this meeting is being recorded and will be available for replay at www.virtualshareholdermeeting.com/siga2026. Even though we are providing a replay, no one attending via the webcast is permitted to use any audio recording device. The agenda and rules of conduct are posted with other meeting materials at the bottom of the webcast screen. The procedures we are following are simple and are designed to ensure that we have a fair and orderly meeting. As Diem explained, the polls are open. Most of you have already voted by proxy, and the proxy votes have been tallied. If you want to vote now or change your vote, you can click on the Vote Here button at the bottom of the webcast screen. The polls will stay open until the conclusion of the review of the matters to be voted on. After the formal meeting has been adjourned, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Your question will not be visible to other participants. Out of consideration for others, please limit yourself to one question. The first order of business for this meeting is the election of our board of directors. The following persons have been nominated to serve as directors until their terms expire and their successors are duly elected and qualified. Mr. Durnan, Mr. Ford, General Keane, Mr. Marshall, Dr. Nabel, Mr. Nemirovsky, Dr. Phillips, and Dr. Nguyen. Additional information about the nominees is available in the proxy statement. We have not received timely notice of any other nominations by a stockholder as required under the bylaws. The second order of business is the proposal to ratify the appointment of PricewaterhouseCoopers, LLP to serve as our independent auditors for fiscal year 2026. Additional information about this proposal is available in the proxy statement. The third order of business is the proposal to approve, on a non-binding basis, the compensation of the company's executive officers. The fourth order of business is the proposal to approve an amendment to the company's amended and restated 2010 Stock Incentive Plan. Thanks, Larry. We will close the polls momentarily. If you have not yet voted and would like to vote, please do so now. I declare the polls closed. Thanks, Diem. I would now like to announce the preliminary results of the voting as reported by the Inspector of Elections. I have received the preliminary report of the Inspector of Elections on each of the matters voted upon by the stockholders. Based thereon, I report that the nominees for election to the board of directors have been duly elected, the ratification of PricewaterhouseCoopers, LLP as our independent registered public accounting firm has received sufficient votes to be approved. The compensation of the company's executive officers has been approved, and the amendment to the company's amended and restated 2010 Stock Incentive Plan has received sufficient votes to be approved. In accordance with the voting, I declare that the nominees for election as directors have been duly elected. PricewaterhouseCoopers, LLP has been ratified as our independent auditors for fiscal year 2026. The compensation of the company's executive officers has been approved, and the amendment to the company's amended and restated 2010 Stock Incentive Plan has been duly approved. The Inspector of Election is directed to file with me a report of the vote of the matters considered at today's meeting. We will be reporting the final vote results in a Form 8-K to be filed within four business days. There is no other business to address during the meeting. I would like to address stockholder questions at this time. Based on our review, there does not appear to be any questions. Thank you very much for your attendance and for your interest in the company. We hope for your attendance again at next year's annual meeting. This concludes today's annual meeting. You may now disconnect